

Alberto D Angelo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1637656/alberto-dangelo-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

317
citations

10
h-index

16
g-index

38
ext. papers

485
ext. citations

4.7
avg, IF

3.98
L-index

#	Paper	IF	Citations
32	p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. <i>Molecules</i> , 2021 , 26,	4.8	2
31	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , 2021 , 101, 108322	5.8	5
30	Darolutamide in hormone-sensitive and castration-resistant prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 535-544	3.8	0
29	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. <i>Gastric Cancer</i> , 2021 , 24, 765-779	7.6	4
28	Second line of treatment for HER2-positive gastric cancer: an evolving issue. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021 , 26, 316-317	1.5	1
27	Maintenance in gastric cancer: New life for an old issue?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103307	7	1
26	Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 83-86	3.3	1
25	Advances in anti-BRAF therapies for lung cancer. <i>Investigational New Drugs</i> , 2021 , 39, 879-890	4.3	8
24	Methylene Blue-Current Knowledge, Fluorescent Properties, and Its Future Use. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
23	TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 103011	7	8
22	MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	30
21	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 623-629	3.8	4
20	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020 , 13, 100795	4.9	14
19	Mutant p53 as an Antigen in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
18	Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. <i>International Reviews of Immunology</i> , 2020 , 39, 223-232	4.6	1
17	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , 2020 , 31, 632-636	2.4	2
16	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 149, 102921	7	3

15	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
14	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. <i>Current Cancer Drug Targets</i> , 2020 , 20, 887-895	2.8	4
13	Corticosteroid switch after progression on abiraterone acetate plus prednisone. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 240-246	4.2	7
12	Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. <i>Cancers</i> , 2020 , 12,	6.6	18
11	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , 2020 , 10, 19281	4.9	4
10	Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1139-1146	3.8	6
9	Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1033-1039	3.6	10
8	Tumor-Agnostic Treatment for Cancer: When How is Better than Where. <i>Clinical Drug Investigation</i> , 2020 , 40, 519-527	3.2	16
7	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. <i>Cells</i> , 2019 , 8,	7.9	70
6	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. <i>PLoS ONE</i> , 2019 , 14, e0219566	3.7	11
5	Avelumab in gastric cancer. <i>Immunotherapy</i> , 2019 , 11, 759-768	3.8	8
4	Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. <i>Journal of Oncology</i> , 2019 , 2019, 5692317	4.5	5
3	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , 2018 , 36, 1133-1137	4.3	14
2	Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. <i>Cells</i> , 2018 , 7,	7.9	32
1	Acute kidney injury following induction of chemotherapy: Diagnosis and management in critical care. <i>Journal of the Intensive Care Society</i> , 175114372211064	1.6	0